STVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stevanato Group SpA (STVN) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows mixed signals with no significant positive catalysts or strong trading signals. While the company has shown slight revenue growth, its net income and EPS have declined. Analyst ratings have been revised downward, and the stock lacks recent news or influential trading activity to drive momentum. Given the investor's profile and the current data, holding off on this investment is recommended.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 78.418, and moving averages are converging, showing no clear trend. The stock's pre-market price is $16.5, nearing the R1 resistance level of $16.723, which could limit further immediate upside.
The company's Q4 2025 revenue increased by 4.81% YoY, and gross margin improved by 3.45% YoY. Analysts note structural growth in biologics and premium formats.
Analysts have lowered price targets, citing near-term engineering weakness and GLP-1 moderation. No recent news or significant trading activity from insiders, hedge funds, or Congress.
In Q4 2025, revenue increased to $346.48M (+4.81% YoY), but net income dropped to $47.56M (-1.57% YoY), and EPS fell to $0.17 (-5.56% YoY). Gross margin improved to 31.81% (+3.45% YoY).
Analysts have lowered price targets across the board, with mixed ratings: Buy from Citi and BofA, Overweight from KeyBanc, and Hold from Jefferies. The focus has shifted to core biologics as GLP-1 revenue growth moderates.
